Abstract 2084P
Background
CV mortality is the leading preventable cause of death in cancer patients. Understanding the timing and quantifying the magnitude of CV mortality can facilitate strategies to reduce mortality.
Methods
Surveillance, Epidemiology, and End Results (SEER) database (2004-2018) were queried to obtain CV mortality (defined as deaths due to heart diseases, hypertension, cerebrovascular diseases, atherosclerosis, aortic aneurysm, and dissection) in metastatic cancer patients. Standardized mortality ratios (SMRs) were calculated (observed deaths from each category divided by the expected number of deaths in the age-matched US population for the same period). SMR was presented by latency periods of <2, 2-5, and >5 years after the initial diagnosis of metastatic cancer and stratified by age (<50 years, 50-70 years, >70 years), race (White, Black, Asian/Pacific Islander, Native American), and ethnicity (Hispanic, Non-Hispanic).
Results
This analysis included 914,804 metastatic cancer patients. Overall, the risk of CV death was highest <2 years of initial diagnosis (SMR: 2.47, 95% CI: 2.35-2.58) compared to population who died 2-5 years (1.22, 1.17-1.27) and 5>years (1.11, 1.03-1.17) after the initial diagnosis. In terms of different subgroups, younger population (age <50 years) observed the highest risk of CV mortality within < 2 years (8.84, 7.5-10.4) except for prostate cancer, where the risk of cardiovascular death becomes highest at >5 years after diagnosis. Similarly, regarding race, Native Americans had the highest risk of CV mortality (6.44, 4.86-8.54), which remained consistent across different cancers. There was significant increase in observed mortality in Hispanic (2.93, 2.62-3.28) and Non-Hispanic (2.43, 2.31-2.55) population. The mortality risk by ethnicity remained consistent with latency periods of <2, 2-5, and > 5years after the initial diagnosis of metastatic cancer.
Conclusions
Metastatic cancer patients who are younger or those who are Native Americans have the highest CV mortality, especially <2 years of initial diagnosis of metastatic disease. Targeted cardio-oncological strategies should be aimed at improving CV mortality in patients who are at highest risk of deaths.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
I.B. Riaz.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2055P - Multidisciplinary Tumor-ICU Board: Enhancing care for critically Ill patients with solid tumors in the ICU
Presenter: Francisco Javier Ros Montana
Session: Poster session 06
2056P - Hospitalization, reconsultations and mortality in the field of oncological emergencies: Who is at higher risk?
Presenter: Eugenia María Martínez Madrid
Session: Poster session 06
2057P - Prevalence of frailty in long-term prostate cancer survivors after radical prostatectomy and its association with quality of life and emotional health
Presenter: Valentin Meissner
Session: Poster session 06
2058P - Reducing waste to improve sustainability and affordability of cancer treatment: Redispensing unused oral anticancer drugs
Presenter: Lisa-Marie Smale
Session: Poster session 06
2059P - The impact of a dental oncology clinic for patients (pts) prescribed bone-modifying agents (BMA) in a cancer centre
Presenter: Harriet Byrne
Session: Poster session 06
2060P - Prevalence and predictor of poor mental adjustment to cancer before lung cancer surgery
Presenter: Junhee Park
Session: Poster session 06
2061P - Network analysis of comprehensive concerns in patients with cancer: Differences between the sexes
Presenter: Kazumasa Yamamoto
Session: Poster session 06
2062P - The psychological distress (PsyD) evaluation in pancreatic cancer (PC) patients (pts): A mono-institutional analysis
Presenter: Maria Bensi
Session: Poster session 06
2063P - Lifestyle changes as cancer treatment: It is time to get specific with our patients
Presenter: Ana Isabel Martin Quesada
Session: Poster session 06
2064P - Hospitalisation of patients with cancer: Identifying points for improvement in patient care in a university hospital in Spain
Presenter: Silvia Roa
Session: Poster session 06